extensive-stage small cell lung cancer
Conditions
Interventions
None listed
Sponsors
Niigata Lung Cancer Treatment Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The patient has been histologically diagnosed with small cell lung cancer. 2. The patient has been diagnosed with extensive-stage small cell lung cancer. Patients with extensive-stage small cell lung cancer or recurrence after radical surgery or radical (chemo)radiation therapy. 3. The patient has received platinum plus etoposide plus immune checkpoint inhibitor combination therapy as initial chemotherapy for advanced small cell lung cancer, and disease progression has been confirmed (including cases in which platinum plus etoposide plus immune checkpoint inhibitor combination therapy was discontinued due to adverse events and disease progression was subsequently observed). 4. AMR monotherapy has been administered as second-line chemotherapy for small cell lung cancer.
Exclusion criteria
Exclusion criteria: 1. Patients deemed inappropriate for enrollment by the principal investigator at each institution
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Response rate, Overall survival, Relationship between time to recurrence and antitumor effect of AMR therapy, Relationship between the occurrence of immune-related adverse events in first-line therapy and the antitumor efficacy and safety of AMR therapy, Relationship between the best treatment effect of first-line therapy and the anti-tumor effect of AMR therapy | — |
Countries
Japan
Contacts
Public ContactSatoshi Watenabe
Niigata University Medical and Dental Hospital Department of Respiratory Medicine and Infectious Diseases
Outcome results
None listed